Fingerprint
Dive into the research topics of 'Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study
Jessica K. Altman*, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota, Michael Keng, Olga Frankfurt, Yasmin Abaza, Dale L. Bixby, Ashkan Emadi, Micah Burch, Bhavana Bhatnagar, Selina M. Luger, Mary Elizabeth Percival, Ofir Wolach, Michael Craig, Chezi Ganzel, Gail Roboz, Itai Levi, Anna Gourevitch
*Corresponding author for this work
- Northwestern University
- Rambam Health Care Campus Israel
- Rutgers - The State University of New Jersey, Newark
- Augusta University
- University of Virginia
- University of Michigan, Ann Arbor
- University of Maryland, Baltimore
- Baylor Scott & White Health
- Ohio State University
- University of Pennsylvania
- University of Washington
- Rabin Medical Center Israel
- West Virginia University
- Shaare Zedek Medical Center
- Cornell University
- Soroka Medical Center
- Biosight Ltd
- Technion-Israel Institute of Technology
Research output: Contribution to journal › Article › peer-review